Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Swedish Orphan Biovitrum (Sobi), an integrated biopharmaceutical company, has signed a global licensing agreement with France-based Only for Children Pharmaceuticals (O4CP) for bumetanide reformulated to treat diuresis and seizures in neonates.
Subscribe to our email newsletter
The drug candidate is currently in clinical phase II under the EU financed NEMO (Treatment of NEonatal seizures with Medication Off-patent project).
Under the collaboration, O4CP will be responsible for obtaining market authorizations and for manufacturing of drug product.
Sobi will take charge of commercialization of the product on a global basis.
The deal involves an upfront payment by Sobi in the amount of 300 000 Euro and potential future milestones of a value up to approximately 1.7m Euro.
O4CP will also receive royalties on future commercial sales.